Finding the optimal partner to pair with bispecific antibody therapy for multiple myeloma.
Finding the optimal partner to pair with bispecific antibody therapy for multiple myeloma.
复制标题
DOI：
10.1158/2643-3230.bcd-21-0073
复制
发表时间：
2021-07
影响因子：
11.2
通讯作者：
Smith EL
中科院分区：
文献类型：
--
作者：
Louvet C;Nadeem O;Smith EL
BCMA/ cd3ε靶向双特异性抗体（BsAb）治疗是治疗复发和难治性多发性骨髓瘤（MM）的一种有前景的t细胞重定向免疫疗法。然而，合理的组合策略很可能是实现持久免疫反应的关键。在这一期中，Meermeier和他的同事研究了BsAb在同基因MM模型中的治疗，并阐明了与环磷酰胺合作与缓和活化，减轻t细胞耗竭有关，并且在增强持久抗MM疗效方面优于泊马度胺或硼替佐米。
BCMA/CD3ε-targeted bispecific antibody (BsAb) therapy represents a promising T-cell redirecting immunotherapy to treat relapsed and refractory multiple myeloma (MM). However, rational combination strategies will most likely be key to achieve a long-lasting immune response. In this issue, Meermeier and colleagues investigate BsAb therapy in a syngeneic MM model and elucidate that partnering with cyclophosphamide is associated with tempered activation, mitigated exhaustion of T-cells, and is superior to pomalidomide or bortezomib in enhancing durable anti-MM efficacy.